Sotera Health Co
For the period ended Nov 3, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 3, 2026 · Filed Nov 3, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Segment Data
Segment Data
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Segment revenues: | ||||
| Sterigenics | $209,305 | $192,845 | $607,011 | $557,368 |
| Nordion | 55,024 | 62,805 | 146,182 | 137,793 |
| Nelson Labs | 60,557 | 55,662 | 173,113 | 165,015 |
| Total net revenues | $324,886 | $311,312 | $926,306 | $860,176 |
| Segment income: | ||||
| Sterigenics | $117,487 | $107,155 | $332,026 | $302,904 |
| Nordion | 33,724 | 38,048 | 85,415 | 78,947 |
| Nelson Labs | 19,454 | 18,987 | 53,616 | 54,913 |
| Total segment income | 170,665 | 164,190 | 471,057 | 436,764 |
| Less adjustments: | ||||
| Interest expense, net | 34,122 | 39,147 | 103,272 | 120,674 |
| Depreciation and amortization(a) | 32,450 | 28,290 | 96,522 | 103,972 |
| Share-based compensation(b) | 7,791 | 8,047 | 29,616 | 23,465 |
| Loss on refinancing of debt(c) | — | 1,087 | 936 | 1,167 |
| Gain on foreign currency and derivatives not designated as hedging instruments, net(d) | (2,101) | (167) | (5,747) | (1,294) |
| Business optimization expenses(e) | 2,387 | 3,098 | 5,267 | 7,575 |
| Professional services relating to EO sterilization facilities(f) | 11,656 | 11,152 | 34,860 | 37,515 |
| Illinois EO litigation settlements(g) | — | — | — | 64,943 |
| Accretion of asset retirement obligation(h) | 628 | 601 | 1,935 | 1,738 |
| Consolidated income before income taxes | $83,732 | $72,935 | $204,396 | $77,009 |
(a)Includes depreciation of Co-60 held at gamma irradiation sites, and excludes accelerated depreciation associated with business optimization activities.
(b)Represents share-based compensation expense related to employees and non-employee Directors.
(c)Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Term Loans and the Revolving Credit Facility.
(d)Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
(e)Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with the secondary offerings and shareholder engagement.
(f)Represents litigation and other professional fees associated with our EO sterilization facilities.
(g)Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.
(h)Represents non-cash accretion of asset retirement obligations (“ARO”) related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.